Marin Biologic Laboratories
Private Company
Funding information not available
Overview
MarinBio is a long-established, privately-held CRO that has successfully transitioned from its historical roots in custom antibody services to a full-service partner for pharmaceutical and biotech companies. The company's core value proposition lies in its deep scientific expertise, regulatory acumen—evidenced by recent successful FDA and EU inspections—and a partnership model focused on client goals. It offers a comprehensive suite of assay development and validation services critical for advancing therapeutics, particularly in cutting-edge fields such as immunotherapy, gene therapy, and targeted protein degradation.
Technology Platform
A versatile toolbox of GMP/GLP-compliant bioanalytical assay technologies and expertise, including cell-based assays, immunoassays (ELISA, flow cytometry), molecular biology (qPCR), and specialized services for advanced modalities like cell therapy, gene therapy, and targeted protein degradation.
Opportunities
Risk Factors
Competitive Landscape
MarinBio competes in a fragmented but crowded CRO market. It differentiates itself from large, full-service CROs by emphasizing deep scientific partnership, senior-led projects, and niche expertise in advanced therapy assays. It competes with other specialized bioanalytical CROs on the basis of its 30-year track record, recent flawless regulatory inspections, and cost-effective positioning.